REFERENCES
1. Butler, S.S., et al., Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate‐specific antigen screening in 2012. Cancer, 2020. 126(4): p. 717-724.
2. Agrawal, V., et al., Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US. JAMA Network Open, 2020. 3(8): p. e2014674.
3. Kaps, B., M. Leapman, and Y. An, Trends in prostatectomy utilization: Increasing upfront prostatectomy and postprostatectomy radiotherapy for high‐risk prostate cancer. Cancer Medicine, 2020. 9(23): p. 8754-8764.
4. Dee, E.C., et al., Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics, 2021. 109(5): p. 1279-1285.
5. Imber, B.S., et al., Financial toxicity associated with treatment of localized prostate cancer. Nature Reviews Urology, 2020. 17(1): p. 28-40.
6. De Vries, K.C., et al., Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial. International Journal of Radiation Oncology*Biology*Physics, 2020. 106(1): p. 108-115.
7. Dearnaley, D., et al., Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. The Lancet Oncology, 2016. 17(8): p. 1047-1060.
8. Catton, C.N., et al., Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 2017. 35(17): p. 1884-1890.
9. Lee, W.R., et al., Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. Journal of Clinical Oncology, 2016. 34(20): p. 2325-2332.
10. Morgan, S.C., et al., Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Practical Radiation Oncology, 2018. 8(6): p. 354-360.
11. Moore, A., et al., The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States. J Oncol, 2019. 2019: p. 8170428.
12. Buyyounouski, M.K., et al., Primary Endpoint Analysis of a Randomized Phase III Trial of Hypofractionated vs. Conventional Post-Prostatectomy Radiotherapy: NRG Oncology GU003. International Journal of Radiation Oncology*Biology*Physics, 2021. 111(3): p. S2-S3.
13. Dasu, A. and I. Toma-Dasu, Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncologica, 2012. 51(8): p. 963-974.
14. Pos, F.J., et al., Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose? International Journal of Radiation Oncology*Biology*Physics, 2006. 64(4): p. 1168-1173.
15. Tucker, S.L., et al., Estimation of α/β for Late Rectal Toxicity Based on RTOG 94-06. International Journal of Radiation Oncology*Biology*Physics, 2011. 81(2): p. 600-605.
16. Marzi, S., et al., Modeling of α/β for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental & Clinical Cancer Research, 2009. 28(1): p. 117.
17. Kruser, T.J., et al., Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer, 2011. 117(12): p. 2629-2636.
18. Michalski, J.M., et al., Development of RTOG Consensus Guidelines for the Definition of the Clinical Target Volume for Postoperative Conformal Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics, 2010. 76(2): p. 361-368.
19. Blanker, M.H., et al., Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire: results from an observational cohort study in Dutch primary care. BMJ Open, 2019. 9(12): p. e032795.
20. Skolarus, T.A., et al., Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form. Urology, 2015. 85(1): p. 101-106.
21. Kroenke, K., F. Baye, and S.G. Lourens, Comparative Responsiveness and Minimally Important Difference of Common Anxiety Measures. Med Care, 2019. 57(11): p. 890-897.
22. Kroenke, K., et al., Minimally important differences and severity thresholds are estimated for the PROMIS depression scales from three randomized clinical trials. Journal of Affective Disorders, 2020. 266: p. 100-108.
23. Bastawros, D., et al., Satisfaction and Regret Following Uterosacral Ligament Suspension and Sacrocolpopexy: A Prospective Multicenter Analysis From the Fellows' Pelvic Research Network. Female Pelvic Med Reconstr Surg, 2021. 27(1): p. e70-e74.
24. Rosen, R.C., et al., Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol, 2011. 60(5): p. 1010-6.
25. Ghadjar, P., et al., Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. Eur Urol, 2021. 80(3): p. 306-315.
26. Qi, X., et al., Toxicity and Biochemical Outcomes of Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Results of a Randomized Phase III Trial. Int J Radiat Oncol Biol Phys, 2020. 106(2): p. 282-290.
27. Wages, N.A., et al., Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 Trial. International Journal of Radiation Oncology*Biology*Physics, 2020.
28. Akthar, A.S., et al., Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. Eur Urol, 2019. 76(5): p. 686-692.
29. Pollack, A., et al., The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. The Lancet, 2022. 399(10338): p. 1886-1901.
30. Sampath, S., et al., Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial. International Journal of Radiation Oncology*Biology*Physics, 2020. 106(3): p. 537-545.
31. Shinde, A., et al., Dosimetric Predictors of Genitourinary Toxicity From a Phase I Trial of Prostate Bed Stereotactic Body Radiation Therapy. Practical Radiation Oncology, 2021. 11(1): p. e90-e97.
32. Poortmans, P., et al., Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiotherapy and Oncology, 2007. 84(2): p. 121-127.
33. Sidhom, M.A., et al., Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiotherapy and Oncology, 2008. 88(1): p. 10-19.
34. Wiltshire, K.L., et al., Anatomic Boundaries of the Clinical Target Volume (Prostate Bed) After Radical Prostatectomy. International Journal of Radiation Oncology*Biology*Physics, 2007. 69(4): p. 1090-1099.
35. Robin, S., et al., Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics, 2021. 109(5): p. 1243-1253.
36. Avkshtol, V., et al., Ten-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer. Journal of Clinical Oncology, 2020. 38(15): p. 1676-1684.
37. Bell, L.J., et al., Intra-fraction displacement of the prostate bed during post-prostatectomy radiotherapy. Radiation Oncology, 2021. 16(1).
38. De Muinck Keizer, D.M., et al., Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac. Radiotherapy and Oncology, 2020. 151: p. 88-94.
39. Ballas, L.K., et al., Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. International Journal of Radiation Oncology*Biology*Physics, 2019. 104(1): p. 50-60.
40. El Kabbaj, O., et al., Target definition in salvage postoperative radiotherapy for prostate cancer: 18F-fluorocholine PET/CT assessment of local recurrence. Acta Oncol, 2018. 57(3): p. 375-381.
41. Harmon, G., et al., Validating Modern NRG Oncology Pelvic Nodal and Groupe Francophone de Radiothérapie Urologique Prostate Bed Contouring Guidelines for Post-prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial. International Journal of Radiation Oncology*Biology*Physics, 2021.
42. Francolini, G., et al., Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series. BJU International, 2020. 125(3): p. 417-425.
43. Buchser, D., et al., Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy. Journal of Contemporary Brachytherapy, 2016. 6: p. 477-483.
44. Kumar, A.M.S., et al., Safety and efficacy of salvage low-dose-rate brachytherapy for prostate bed recurrences following radical prostatectomy. Journal of Contemporary Brachytherapy, 2015. 4: p. 241-246.
45. Glicksman, R.M., et al., Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trials. Radiother Oncol, 2021. 163: p. 159-164.
46. Bauman, G., et al., A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys, 2015. 92(4): p. 856-62.